| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.17 | 0.001 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.1 | 0.002 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.094 | 0.002 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.003 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.003 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | -0.14 | 0.003 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.005 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.005 |